Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2025-12-26 @ 5:13 PM
Study NCT ID:
NCT03520959
Status:
TERMINATED
Last Update Posted:
2020-04-16
First Post:
2018-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Sponsor:
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-18
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-11-20
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-30
First Submit QC Date:
None
Study First Post Date:
2018-05-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-02-26
Results First Submit QC Date:
None
Results First Post Date:
2020-04-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-03
Last Update Post Date:
2020-04-16
Last Update Post Date Type:
ACTUAL